Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human TA-46 single- and multiple-ascending-dose study in healthy volunteers
NL-OMON48911Phase 1Active, not recruiting
- Sponsor
- Therachon
- Start
- Jan 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recifercept in achondroplasia (ACH) (6 arms), sponsored by Therachon. Primary endpoint: Safety and tolerability of TA-46. Started Jan 2018; status: active, not recruiting.
02
Drugs
recifercept
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NL-OMON48911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48911.